AptarGroup, Inc. reported a strong 14% increase in reported sales and 5% core sales growth in the fourth quarter of 2025, with all three segments contributing to core sales growth. However, reported net income decreased by 26% to $74 million, and adjusted EBITDA margin was 19.8%, down from 23.0% in the prior year, primarily due to product mix and higher production costs.

Aptar posted strong Q3 2025 results with a 6% sales increase to $961 million and net income rising to $128 million. EPS grew to $1.92, and adjusted EPS reached $1.62. The pharma segment led with 18% growth in injectables. Adjusted EBITDA margin improved to 23.2%.

AptarGroup delivered a solid second quarter in 2025, with reported sales increasing by 6% and core sales by 3%. Net income rose by 24% to $112 million, and reported EPS increased by 25% to $1.67. All segments contributed positively, with Pharma and Closures driving growth through increased volumes and higher-value products. The company also returned $100 million to shareholders through share repurchases and dividends.

AptarGroup's Q1 2025 results showed a slight revenue decline and lower net income, driven by weaker performance in Beauty and Closures segments, partially offset by strong demand in Pharma, especially for emergency medicine and diabetes care solutions.

Aptar reported strong Q4 results with net income surging 62% year-over-year, driven by increased demand in pharma and closures segments. Adjusted EPS rose 27% while core sales grew 2%.

AptarGroup's Q3 2024 results showed a 2% increase in both reported and core sales, driven by the Pharma and Closures segments. Net income increased by 19% to $100 million, and adjusted EPS rose by 6% to $1.49.

AptarGroup's second quarter 2024 results showed a 2% increase in reported sales and a 3% increase in core sales. Net income increased by 9% to $90 million, with earnings per share rising by 8% to $1.34 and adjusted earnings per share increasing by 12% to $1.37. The Pharma segment delivered strong sales growth, and margins improved due to higher value product sales and cost management efforts.

AptarGroup reported a strong first quarter with a 6% increase in reported sales and a 5% increase in core sales. Net income increased by 52% to $83 million, with reported earnings per share up 50% to $1.23 and adjusted earnings per share up 31% to $1.26.

AptarGroup's Q4 2023 results showed a 5% increase in reported sales and a 2% increase in core sales. Net income increased by 6% to $62 million. Adjusted earnings per share increased 27% to $1.21. The Pharma segment experienced over 20% core sales growth in proprietary dosing and dispensing systems.

AptarGroup reported a 7% increase in reported sales and a 2% increase in core sales. Net income increased by 55% to $84 million. Earnings per share increased by 56% to $1.26, and adjusted earnings per share increased by 39% to $1.39.

AptarGroup's Q2 2023 results showed strong operational performance, driven by proprietary drug delivery systems and fragrance dispensing solutions. Reported sales increased by 6%, core sales increased by 4%, and net income increased by 31% to $83 million.

AptarGroup reported a positive start to 2023, with a 2% increase in reported sales and a 4% increase in core sales, driven by the Pharma and Beauty segments. Net income decreased by 12% to $55 million due to restructuring charges, while adjusted earnings per share increased by 2% to $0.95.

AptarGroup's Q4 2022 results showed a mixed performance, with net income increasing by 2% but reported sales decreasing by 2%. Core sales, excluding currency and acquisition effects, increased by 4%. The company saw strong volume growth in its consumer healthcare and prescription divisions, as well as in beauty dispensing solutions for prestige fragrance and skincare.

AptarGroup's Q3 2022 results showed a 15% increase in net income to $54 million, with core sales up 9%. The Pharma segment drove growth with double-digit core sales increases, while Beauty + Home faced supply chain issues in North America. The company expects continued growth in Pharma but anticipates softening demand in personal care, food, and beverage markets.

AptarGroup reported a positive second quarter with a 4% increase in reported sales and a 15% increase in net income. Core sales grew by 10%, and adjusted EBITDA increased by 8%. The company is focused on pricing initiatives and managing expenses to drive shareholder return.

AptarGroup reported a 9% increase in sales to $845 million, with core sales up 13%. The company experienced double-digit core sales growth in each segment. Reported earnings per share were $0.93, and adjusted earnings per share were $0.96.

AptarGroup reported a 9% increase in sales, reaching $814 million, with core sales up 10%. Earnings per share increased by 8% to $0.85, and adjusted earnings per share rose by 3% to $0.93. Net income increased by 8% to $58 million.

AptarGroup reported a 9% increase in sales, primarily driven by double-digit core sales growth in Beauty + Home and Food + Beverage. Pharma sales declined slightly. Earnings per share were $0.70, and adjusted earnings per share were $0.94. The company completed acquisitions of Weihai Hengyu Medical Products and a majority stake in Voluntis.

AptarGroup reported a 16% increase in sales to $811 million, driven by strong core sales growth and positive currency effects. Core sales increased by 10%, with double-digit growth in Beauty + Home and Food + Beverage segments. Earnings per share were $0.81, and adjusted earnings per share were $0.91.

AptarGroup reported an 8% increase in sales to $777 million for Q1 2021, with core sales up by 1%. Adjusted earnings per share totaled $1.09, a 10% increase compared to the prior year, neutralizing currency effects. The Food + Beverage segment demonstrated strong growth, while the Pharma and Beauty + Home segments experienced varied performance due to market-specific factors and pandemic-related impacts.

AptarGroup reported strong fourth quarter performance with reported sales growth of 12% and core sales growth of 5%. The Pharma and Food + Beverage segments achieved double-digit sales growth, while the Beauty + Home segment saw modest core sales decline. The company achieved increased earnings per share and strong cash flow from operations and free cash flow.

AptarGroup reported an 8% increase in sales to $759 million with a 2% increase in core sales during Q3 2020. The Pharma segment showed strong growth, while Beauty and Beverage segments were impacted by COVID-19. Earnings per share increased to $0.95, and adjusted earnings per share rose to $1.00.

AptarGroup reported a 6% decrease in sales for the second quarter of 2020, primarily due to the negative impacts of COVID-19 on the beauty and beverage markets. The Pharma segment experienced growth, but it was not enough to offset declines in other segments. Earnings per share decreased by 44% to $0.63, while adjusted earnings per share decreased by 30% to $0.80.

AptarGroup's Q1 2020 results showed a decrease in reported sales by 3% to $722 million, with core sales, excluding currency and acquisition effects, decreasing by 2%. EPS was $0.84, a decrease of 13% compared to the prior year. The Pharma segment saw core sales growth of 7%, offsetting declines in other segments. The company is deemed an essential supplier and is monitoring the COVID-19 pandemic's impact.

AptarGroup reported a decrease in sales for Q4 2019, with reported sales at $671 million, a 2% decrease compared to the previous year, impacted by currency exchange rates and lower resin costs. The Pharma segment experienced core sales growth, which was offset by decreases in other segments. Reported earnings per share were $0.73, while adjusted earnings per share were $0.80.